Posaconazole Tablet Formulation at 400 Milligrams Daily Achieves Desired Minimum Serum Concentrations in Adult Patients with a Hematologic Malignancy or Stem Cell Transplant

Aaron N Pham; Joseph S Bubalo; James S Lewis 2nd

doi:10.1128/AAC.01489-16

Posaconazole Tablet Formulation at 400 Milligrams Daily Achieves Desired Minimum Serum Concentrations in Adult Patients with a Hematologic Malignancy or Stem Cell Transplant

Antimicrob Agents Chemother. 2016 Oct 21;60(11):6945-6947. doi: 10.1128/AAC.01489-16. Print 2016 Nov.

Authors

Aaron N Pham¹, Joseph S Bubalo², James S Lewis 2nd²

Affiliations

¹ Department of Pharmacy, Oregon Health & Science University Hospital and Clinics, Portland, Oregon, USA phaaa@ohsu.edu.
² Department of Pharmacy, Oregon Health & Science University Hospital and Clinics, Portland, Oregon, USA.

Abstract

We describe our experience using the posaconazole 400-mg delayed-release tablet formulation once daily in 20 patients with hematologic malignancy or hematopoietic stem cell transplant who were unable to attain prespecified target minimum serum (trough) concentrations for treatment or prophylaxis of invasive fungal infection. The higher dose allowed the majority of patients to achieve prespecified target trough concentrations without incurring additional toxicities.

Publication types

Clinical Trial

MeSH terms

Adult
Aged
Antifungal Agents / administration & dosage
Antifungal Agents / blood
Delayed-Action Preparations / administration & dosage
Delayed-Action Preparations / pharmacokinetics
Dose-Response Relationship, Drug
Female
Hematologic Neoplasms* / complications
Hematologic Neoplasms* / microbiology
Hematopoietic Stem Cell Transplantation*
Humans
Male
Middle Aged
Mycoses / prevention & control*
Retrospective Studies
Tablets
Treatment Outcome
Triazoles / administration & dosage
Triazoles / blood*

Substances

Antifungal Agents
Delayed-Action Preparations
Tablets
Triazoles
posaconazole